---
title: "PHIGuard for Oncology Practices"
practiceType: "Oncology practice"
description: "PHIGuard helps oncology practices manage HIPAA compliance across treatment records, clinical-trial PHI, infusion scheduling, and workforce training with current pricing."
metaDescription: "HIPAA compliance for oncology practices: clinical-trial PHI, infusion records, workforce training, and audit trails. PHIGuard publishes BAA details on the."
publishedAt: 2026-04-24
updatedAt: 2026-04-24
verificationDate: 2026-04-24
summary: "Oncology practices handle some of the most sensitive PHI in medicine — diagnoses with significant personal and financial consequences, treatment records, and often clinical-trial data that intersects HIPAA with additional federal research regulations. PHIGuard provides the compliance infrastructure to keep that work auditable with current pricing."
sources:
  - title: "Summary of the HIPAA Privacy Rule"
    url: "https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html"
    publisher: "HHS"
  - title: "HIPAA Privacy Rule and Clinical Research"
    url: "https://www.hhs.gov/hipaa/for-professionals/special-topics/research/index.html"
    publisher: "NIH"
  - title: "45 CFR 164.512(i) — Disclosures for Research"
    url: "https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-C/part-164/subpart-E/section-164.512"
    publisher: "eCFR"
faq:
  - q: "How does HIPAA interact with clinical trial data in an oncology practice?"
    a: "A patient's participation in a clinical trial, and any PHI generated during the trial, is subject to the HIPAA Privacy Rule if the practice is a covered entity. Using or disclosing that PHI for research purposes generally requires either an IRB-approved waiver of authorization or a valid individual authorization under 45 CFR 164.512(i). The practice must coordinate with its IRB and sponsor on which mechanism applies."
  - q: "Are cancer diagnoses treated differently under HIPAA than other diagnoses?"
    a: "HIPAA does not create a separate tier for cancer diagnoses, but the sensitivity of an oncology diagnosis — and the potential consequences of unauthorized disclosure for insurance, employment, or personal relationships — means access controls and minimum necessary disclosures matter more in practice. State laws may provide additional protections."
  - q: "What PHI risks come with infusion center scheduling?"
    a: "The infusion schedule links patient identity to treatment dates and implicitly to treatment type. A schedule posted in a visible area, emailed without encryption, or shared with non-essential staff is a Privacy Rule exposure. Access controls on scheduling records should match the sensitivity of the data."
author: "angel-campa"
reviewer: "phiguard-compliance-research"
relatedResource: "hipaa-compliance-self-assessment"
relatedCommercialPath: "/hipaa"
relatedLearnPath: "/learn/hipaa-basics/what-is-phi"
---

Oncology practices manage PHI at a level of sensitivity that has real consequences for patients beyond the clinical setting. A cancer diagnosis can affect insurance eligibility, employment, and personal relationships. Patients are acutely aware that this information is sensitive. Practices that handle it without deliberate compliance controls create both legal exposure and patient trust problems.

## PHI Risks Specific to Oncology Practices

**Infusion scheduling records.** The infusion center schedule links patient identity to treatment dates. In a community oncology practice, that schedule is visible to multiple staff members and is often managed in systems that also serve scheduling functions for other departments. Access should be limited to staff with a direct treatment role. A schedule printout left in a common area or emailed in plain text is a Privacy Rule exposure.

**Treatment records and chemotherapy orders.** Chemotherapy order records are detailed, include specific drug regimens, and reference underlying diagnoses. These records move between oncology nurses, pharmacists, and infusion staff. Each handoff is a PHI transmission point that needs documented handling protocols and, where electronic, Security Rule-compliant controls.

**Clinical trial PHI.** Many community oncology practices enroll patients in cooperative group trials or sponsored research. PHI generated during a trial is subject to the HIPAA Privacy Rule, and its use for research purposes requires either IRB approval with a waiver of authorization or a HIPAA-compliant individual authorization. Practices must coordinate with the trial sponsor and IRB to determine which mechanism applies before sharing trial PHI.

**Genetic information.** Tumor genomic profiling and germline genetic testing are increasingly standard in oncology. Genetic information is PHI under 45 CFR 160.103. The HIPAA Privacy Rule, as amended by GINA (the Genetic Information Nondiscrimination Act of 2008) and the HITECH Act, prohibits health plans from using genetic information for underwriting purposes and imposes additional restrictions on its disclosure. For oncology practices, this means results from germline testing (BRCA, Lynch syndrome panels, and similar) warrant role-based access controls tighter than standard clinical records. Results from third-party genomic labs require BAAs and documented access controls.

**Tumor registry reporting.** Most states require oncology practices and the facilities where cancer cases are diagnosed and treated to report cases to the state cancer registry. These mandatory reports are permitted disclosures under 45 CFR 164.512(b) without individual patient authorization, but the practice must document the legal basis for each report. Some cancer registries also receive data from the National Cancer Institute's SEER program, which involves additional data use agreements. The registry vendor handling data submission is a business associate and requires a BAA.

**Multi-provider coordination.** An oncology patient's care team often includes a medical oncologist, a radiation oncologist, a surgical oncologist, a palliative care specialist, and the patient's primary care physician. Coordinating records across that group involves multiple disclosure events, each of which must comply with the Privacy Rule's treatment purpose exception or a valid authorization.

## Common Compliance Gaps

Oncology practices most often identify two recurring compliance gaps: no formal BAA with the genomic testing laboratories that provide sequencing results, and training documentation that covers the clinical team but misses front desk and scheduling staff who have significant access to the infusion schedule and patient contact records.

## What PHIGuard Provides

PHIGuard provides oncology practice administrators with a compliance management platform that does not require a compliance officer to operate. The platform includes:

- **Training tracking** per §164.530(b), with timestamps for every staff member
- **Incident log** with guided breach risk assessment per 45 CFR 164.402
- **BAA inventory** for genomic labs, infusion pharmacy partners, and trial sponsors
- **Compliance task templates** for annual risk analysis, policy review, and training cycles
- **Immutable audit trail** on all compliance records


## Related Resources

- [PHIGuard for neurology practices](/practice-types/neurology-practice)
- [What is PHI under HIPAA?](/learn/hipaa-basics/what-is-phi)
- [HIPAA breach notification requirements](/learn/incident-response/hipaa-breach-notification-timelines)

## Documentation discipline for oncology practices

Oncology practices create PHI across diagnosis and staging records, pathology, infusion notes, radiation referrals, genetic testing, specialty pharmacy coordination, financial assistance, and clinical-trial-adjacent workflows. The compliance risk is not only whether the clinical record exists. It is whether the practice can show who owned the follow-up, what vendor or partner touched patient information, and when the task was completed. PHIGuard gives that operational work a HIPAA-native place to live instead of scattering it across inboxes, paper notes, spreadsheets, or memory.

The highest-value evidence set includes sensitive diagnosis data, specialty drug coordination, vendor BAAs, staff access, training, and incident response. Common external relationships to review include hospitals, labs, specialty pharmacies, infusion vendors, patient support programs, billing services, and research partners. PHIGuard tracks those items as assigned tasks with due dates, completion history, and supporting notes. That creates a reviewable record for the administrator, owner, or compliance lead without turning the clinical system itself into a generic project tool.

A practical cadence for this specialty is monthly specialty pharmacy and pathology review, quarterly vendor and access checks, annual workforce training, and immediate logging for wrong-recipient oncology records. The cadence should stay grounded in official HHS and OCR source posture: workforce safeguards, security controls, minimum necessary access, audit controls, business associate oversight, and documented incident response. PHIGuard does not replace the EHR, specialty platform, or qualified legal counsel. It helps the practice operate the repeatable compliance work around those systems.

This matters most when the work crosses organizational boundaries. If a record, message, report, image, form, or authorization goes to the wrong place, the practice needs more than a verbal explanation. It needs an incident record, assigned containment steps, follow-up owners, and a clear history of staff training and vendor review. PHIGuard keeps that history tied to the workflow so the practice can explain what happened and what changed afterward.
